A carregar...
Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia
Pazopanib (Votrient) is an orally administered tyrosine kinase inhibitor that blocks VEGF receptors potentially serving as anti-angiogenic treatment for hereditary hemorrhagic telangiectasia (HHT). We report a prospective, multi-center, open-label, dose-escalating study [50 mg, 100 mg, 200 mg, and 4...
Na minha lista:
| Publicado no: | Angiogenesis |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Netherlands
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6510884/ https://ncbi.nlm.nih.gov/pubmed/30191360 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10456-018-9646-1 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|